Vasopressin decreases portal vein pressure and flow in the native liver during liver transplantation
Gebhard Wagener, Gina Gubitosa, John Renz, Milan Kinkhabwala, Tricia Brentjens, James V. Guarrera, Jean Emond, H. Thomas Lee, Donald Landry – 29 October 2008 – Vasodilation due to impaired vascular tone is common in liver failure. Vasoconstrictor drugs are almost always required during the anhepatic phase of a liver transplant to maintain blood pressure unless venovenous bypass is employed.
Healy's law and the pediatric liver allograft
Alex S. Knisely, Richard J. Thompson – 29 October 2008
Paralysis in the left phrenic nerve after living‐donor liver transplantation for biliary atresia with situs inversus
Yukihiro Sanada, Koichi Mizuta, Youichi Kawano, Satoshi Egami, Makoto Hayashida, Shuji Hishikawa, Hideo Kawarasaki – 29 October 2008 – A 7‐month‐old boy with biliary atresia accompanied by situs inversus and absent inferior vena cava (IVC) underwent living‐donor liver transplantation (LDLT). Because a constriction in the recipient hepatic vein (HV) was detected during the preparation of the HV in LDLT, a dissection in the cranial direction and a total clamp of the suprahepatic IVC was performed, and the suprahepatic IVC and the graft HV were anastomosed end‐to‐end.
Liver transplantation and subsequent risk of cancer: Findings from a Canadian cohort study
Ying Jiang, Paul J. Villeneuve, Stanley S. A. Fenton, Douglas E. Schaubel, Les Lilly, Yang Mao – 29 October 2008 – Characterization of the long‐term cancer risks among liver transplant patients has been hampered by the paucity of sufficiently large cohorts. The increase over time in the number of liver transplants coupled with improved survival underscores the need to better understand associated long‐term health effects. This is a cohort study whose subjects were assembled with data from the population‐based Canadian Organ Replacement Registry.
Liver function critically determines serum retinol‐binding protein 4 (RBP4) levels in patients with chronic liver disease and cirrhosis
Frank Tacke, Ralf Weiskirchen, Christian Trautwein – 29 October 2008
Reduced glutathione in the liver as a potential viability marker in non–heart‐beating donors
Markus Golling, Heidi Kellner, Hamidreza Fonouni, Morva Tahmasbi Rad, Renate Urbaschek, Raoul Breitkreutz, Martha Maria Gebhard, Arianeb Mehrabi – 29 October 2008 – Although the use of non–heart‐beating donors (NHBD) is the oldest type of organ transplantation, the results were and still are disappointing. To consider using a liver from NHBD, it is of importance to assess the graft viability. Our aim was to assess the role of reduced liver glutathione (rGSHL) as a potential predictive marker of liver function before transplantation.
Reshaping AAV vectors for liver gene therapy
Florian Kühnel, Stefan Kubicka – 29 October 2008
The transplantation candidate with alcohol misuse: The selection minefield
Hugo E. Vargas, Lois Krahn – 29 October 2008
Dynamic metabonomic analysis of BALB/C mice with different outcomes after D‐galactosamine/lipopolysaccharide–induced fulminant hepatic failure
Bo Feng, Shengming Wu, Sa Lv, Junjian Fang, Feng Liu, Yu Li, Yan Gao, Xianzhong Yan, Fangting Dong, Lai Wei – 29 October 2008 – Fulminant hepatic failure (FHF) is one of the most challenging gastrointestinal emergencies encountered in clinical practice. Early identification of patients with FHF who need liver transplantation is very important. To construct a prediction model for the early diagnosis and prognosis of FHF, we studied the dynamics of metabolic intermediates and metabolic profiles with a D‐galactosamine (GalN)/lipopolysaccharide (LPS)–treated BALB/c mouse model of FHF.